refractory rheumatoid arthritis
Conditions
Interventions
Case series:Plasma exchange combined with lymphocyte removal was performed for the enrolled patients.
Sponsors
Southwest Hospital Chongqing
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients was diagnosed with rheumatoid arthritis by the department of integrated traditional and western medicine in our hospital, and the routine treatment includes the slow action drugs that continue to improve the condition of DMARDS for more than 3 months; and/or continuously stable small dose (less than or equal to 10mg/ day) with hormones for more than one month; the DAS score was still greater than 5.1 (severe disease activity); or the patient have been some adverse reactions as follows after using DMARDS: the leukocyte reduction caused by bone marrow suppression, abnormal liver function and others; and the patient cant use the biological agents or the patient hasnt the sufficient funds for using; 2. Patients havent using the biological agents for nearly three months; 3. Patients havent serious functional abnormality in viscera (heart, lung, liver, kidney); 4. Patients havent obvious coagulation dysfunction; (We cant accept the patient if the value of PT and APTT of the patient were higher than 1.5 times the normal value. However, the patient can be accepted if the value of PT and APTT are lower than or equal to 1.5 times the normal value after treated); 5. Patients havent nontherapeutic anemia (The lymphocyte removal therapy requires the patient's hematocrit in a certain range. Therefore, we cant accept the patient add to this study if the hematocrit of patients cant reach to the normal value through transfusion therapy); 6. Patients havent transfusion-transmittable infections (AIDS, hepatitis c, hepatitis b, syphilis); 7. The pregnancy test for women patients was negative; 8. The patient can cooperate with the observation of curative effect and adverse reaction; 9. Patient aged 18 to 60 years.
Exclusion criteria
Exclusion criteria: (1) Patients have serious functional abnormality in viscera (heart, lung, liver, kidney). (2) Patients have some diseases as follows: Coronary heart disease; Hypertension; Cancer; (3) Patients have obvious coagulation dysfunction; (When the value of PT and APTT of the patient was higher than 1.5 times the normal value, we can accept the patient add to this study if the value can be decreased to the normal value after treatment); (4) Patients have nontherapeutic anemia; (5) Pregnancy or breast-feeding women; (6) Patients have any transfusion-transmittable infections (AIDS, hepatitis c, hepatitis b, syphilis); (7) The patient or his legal representative did not sign on informed consent; (8) The patient cant be cooperate with the observation of curative effect and adverse reaction; (9) Patients with aged younger than 18 years or older than 60 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Activity Score; | — |
Countries
China
Contacts
Public ContactHua Lu
Transfusion Department of Southwest Hospital
Outcome results
None listed